Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Medtronic
Chubb
Daiichi Sankyo
Express Scripts
Cipla
Cerilliant
McKesson
Merck
Harvard Business School

Generated: December 12, 2017

DrugPatentWatch Database Preview

Allergan Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN INC, and what generic alternatives to ALLERGAN INC drugs are available?

ALLERGAN INC has two approved drugs.

There are eight US patents protecting ALLERGAN INC drugs on ALLERGAN INC drugs in the past three years.

There are fifty-six patent family members on ALLERGAN INC drugs in twenty-five countries.

Summary for Allergan Inc

International Patents:56
US Patents:8
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: 4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan IncRHOFADEoxymetazoline hydrochlorideCREAM;TOPICAL208552-001Jan 18, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan IncRHOFADEoxymetazoline hydrochlorideCREAM;TOPICAL208552-001Jan 18, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan IncRHOFADEoxymetazoline hydrochlorideCREAM;TOPICAL208552-001Jan 18, 2017RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan IncRHOFADEoxymetazoline hydrochlorideCREAM;TOPICAL208552-001Jan 18, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Allergan Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016► Subscribe► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016► Subscribe► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALLERGAN INC drugs

Drugname Dosage Strength Tradename Submissiondate
dapsoneGel7.5%ACZONE2/13/2017

Non-Orange Book Patents for Allergan Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,017,231,985► Subscribe
8,877,793Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists► Subscribe
8,815,929Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Allergan Inc Drugs

Country Document Number Estimated Expiration
Australia4261097► Subscribe
Eurasian Patent Organization008022► Subscribe
Slovenia1485059► Subscribe
Iceland7419► Subscribe
Austria353628► Subscribe
Portugal1485059► Subscribe
World Intellectual Property Organization (WIPO)9810746► Subscribe
Canada2265461► Subscribe
Australia2002306767► Subscribe
Australia2016238909► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
QuintilesIMS
Express Scripts
Colorcon
Mallinckrodt
US Department of Justice
Dow
Medtronic
Daiichi Sankyo
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot